Qlife signs letter of intent with major industry partner as part of a the b2b strategy to enter major markets with Egoo Health, through hospital-at-home partnerships.
Qlife is pleased to announce that it has signed a Letter of Intent (LOI) with major industry player, Hipro Biotechnology, to introduce Egoo Health to the Chinese market. Qlife anticipate finalizing a comprehensive collaboration agreement by the end of this year.The technology and overall strategy Qlife has invested more than SEK 300 million in the development of Egoo Health, a unique biomarker self-testing system for measuring and monitoring blood data at clinical-grade level at-home, during clinical trials and for other purposes. The technology was successfully commercialized during the